Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Finch Therapeutics Group's quarterly market cap
declined
from Dec. 2023 ($5.80 Mil) to Mar. 2024 ($4.18 Mil) and
declined
from Mar. 2024 ($4.18 Mil) to Jun. 2024 ($2.20 Mil).
Finch Therapeutics Group's annual market cap
declined
from Dec. 2021 ($473.77 Mil) to Dec. 2022 ($23.07 Mil) and
declined
from Dec. 2022 ($23.07 Mil) to Dec. 2023 ($5.80 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Finch Therapeutics Group's Enterprise Value for Today is $16.38 Mil.
Finch Therapeutics Group (OTCPK:FNCHQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Finch Therapeutics Group Market Cap Related Terms
Finch Therapeutics Group Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Finch Therapeutics Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Finch Therapeutics Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Finch Therapeutics Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Finch Therapeutics Group's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group (FNCHQ) has a Market Cap of $16.38 Mil as of Aug. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's Market Cap too high?
Finch Therapeutics Group's current Market Cap is $16.38 Mil. The Biotechnology industry median Market Cap is 117.56. Finch Therapeutics Group's value of $16.38 Mil is 86.1% below this industry median. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's Market Cap compare to CRIS and LSB?
Finch Therapeutics Group's Market Cap of $16.38 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 117.56. Finch Therapeutics Group's value of $16.38 Mil is 86.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.56, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Finch Therapeutics Group's current Market Cap of $16.38 Mil is 86.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Finch Therapeutics Group and its competitors. For the Biotechnology industry, the median Market Cap is 117.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Finch Therapeutics Group's current Market Cap is $16.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current Market Cap of $16.38 Mil. The current Market Cap is $16.38 Mil and 86.1% below the Biotechnology industry median of 117.56. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current Market Cap is $16.38 Mil as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score
Get the complete analysis for FNCHQ
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FNCHQ has been successfully added to your 
